BriaCell Therapeutics Ownership 2024 | Who Owns BriaCell Therapeutics Now?


OverviewFinancialsChart

Institutional Ownership

0.00%

Insider Ownership

15.56%

Retail Ownership

84.44%

Institutional Holders

1.00

BriaCell Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ROSENBERG MATTHEW HAMILTON0.00%-12--34Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----300-100.00%-Mar 31, 2024

BriaCell Therapeutics's largest institutional shareholder is ROSENBERG MATTHEW HAMILTON, holding 0.00% of the company's total share outstanding, currently valued at $34.00. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ROSENBERG MATTHEW HAMILTON0.00%-12--34Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----300-100.00%-Mar 31, 2024

The largest BriaCell Therapeutics shareholder by % of total assets is ROSENBERG MATTHEW HAMILTON. The company owns 12.00 shares of BriaCell Therapeutics (BCTX), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ROSENBERG MATTHEW HAMILTON0.00%-12--34Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----300-100.00%-Mar 31, 2024

As of Mar 31 2024, BriaCell Therapeutics's largest institutional buyer is ROSENBERG MATTHEW HAMILTON. The company purchased 0.00 stocks of BCTX, valued at $34.00.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ADVISORY SERVICES NETWORK, LLC----300-100.00%-Mar 31, 2024
ROSENBERG MATTHEW HAMILTON0.00%-12--34Mar 31, 2024

As of Mar 31 2024, BriaCell Therapeutics's biggest institutional seller is ADVISORY SERVICES NETWORK, LLC. The company sold -0.30K shares of BCTX, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ADVISORY SERVICES NETWORK, LLC----300-100.00%-Mar 31, 2024

BriaCell Therapeutics's largest sold out institutional shareholder by shares sold is ADVISORY SERVICES NETWORK, LLC, sold -0.30K shares, valued at -, as of undefined.

BriaCell Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
WASATCH FUNDS TRUST0.07%609,978--Mar 31, 2024
WASATCH FUNDS TRUST0.03%266,167--Mar 31, 2024
Collaborative Investment Series Trust0.02%4,039--Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%7,229--Feb 29, 2024

BriaCell Therapeutics's largest mutual fund holder by % of total assets is "WASATCH FUNDS TRUST", owning 609.98K shares, compromising 0.07% of its total assets.

BriaCell Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 241-50.00%
31 Dec, 232-
30 Sep, 232-91.30%
30 Jun, 23239.52%
31 Mar, 2321-4.55%
31 Dec, 2222-15.38%
30 Sep, 2226-
30 Jun, 222618.18%
31 Mar, 2222-15.38%
31 Dec, 212636.84%
30 Sep, 2119-9.52%
30 Jun, 2121162.50%
31 Mar, 218-
30 Sep, 201-
30 Jun, 201-

As of 31 Mar 24, 1 institutions are holding BriaCell Therapeutics's shares, representing a decrease of -50.00% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 2412-96.15%
31 Dec, 23312-99.98%
30 Sep, 231,582,462-42.71%
30 Jun, 232,762,3338.46%
31 Mar, 232,546,864-4.40%
31 Dec, 222,663,9895.14%
30 Sep, 222,533,722-14.62%
30 Jun, 222,967,707-10.13%
31 Mar, 223,302,277150.55%
31 Dec, 211,318,024123.47%
30 Sep, 21589,806-83.06%
30 Jun, 213,480,828827.77%
31 Mar, 21375,182-
30 Sep, 20774-
30 Jun, 20774-

BriaCell Therapeutics (BCTX) has 12.00 shares outstanding as of 31 Mar 24, down -96.15% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 240.00%2110.53%
31 Dec, 230.00%0.00%
30 Sep, 2310.20%3.22%
30 Jun, 2317.80%6.61%
31 Mar, 2316.41%5.57%
31 Dec, 2217.17%6.44%
30 Sep, 2216.33%4.46%
30 Jun, 2219.12%4.22%
31 Mar, 2221.28%28.90%
31 Dec, 218.58%61.49%
30 Sep, 213.74%0.72%
30 Jun, 2122.80%376.07%
31 Mar, 212.46%-
30 Sep, 200.01%19607.84%
30 Jun, 200.01%-

As of 31 Mar 24, BriaCell Therapeutics is held by 0.00% institutional shareholders, representing a 2110.53% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 24--100.00%
31 Dec, 231-
30 Sep, 23--100.00%
30 Jun, 231110.00%
31 Mar, 2310-23.08%
31 Dec, 2213-7.14%
30 Sep, 2214-6.67%
30 Jun, 221536.36%
31 Mar, 2211-45.00%
31 Dec, 212053.85%
30 Sep, 2113-35.00%
30 Jun, 2120150.00%
31 Mar, 218-
30 Sep, 20--100.00%
30 Jun, 201-

- institutional shareholders have increased their position in BCTX stock as of 31 Mar 24 compared to 1 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 24--
31 Dec, 23--100.00%
30 Sep, 231-80.00%
30 Jun, 23525.00%
31 Mar, 234-
31 Dec, 224-20.00%
30 Sep, 225-28.57%
30 Jun, 227-12.50%
31 Mar, 228166.67%
31 Dec, 213-40.00%
30 Sep, 215-
30 Jun, 21--
31 Mar, 21--
30 Sep, 20--
30 Jun, 20--

- institutional shareholders have reduced their position in BCTX stock as of 31 Mar 24 compared to - in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 241-50.00%12-96.15%0.00%2110.53%--100.00%--
31 Dec, 232-312-99.98%0.00%0.00%1---100.00%
30 Sep, 232-91.30%1,582,462-42.71%10.20%3.22%--100.00%1-80.00%
30 Jun, 23239.52%2,762,3338.46%17.80%6.61%1110.00%525.00%
31 Mar, 2321-4.55%2,546,864-4.40%16.41%5.57%10-23.08%4-
31 Dec, 2222-15.38%2,663,9895.14%17.17%6.44%13-7.14%4-20.00%
30 Sep, 2226-2,533,722-14.62%16.33%4.46%14-6.67%5-28.57%
30 Jun, 222618.18%2,967,707-10.13%19.12%4.22%1536.36%7-12.50%
31 Mar, 2222-15.38%3,302,277150.55%21.28%28.90%11-45.00%8166.67%
31 Dec, 212636.84%1,318,024123.47%8.58%61.49%2053.85%3-40.00%
30 Sep, 2119-9.52%589,806-83.06%3.74%0.72%13-35.00%5-
30 Jun, 2121162.50%3,480,828827.77%22.80%376.07%20150.00%--
31 Mar, 218-375,182-2.46%-8---
30 Sep, 201-774-0.01%19607.84%--100.00%--
30 Jun, 201-774-0.01%-1---

BriaCell Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 28, 2022Bondarenko Jamiesonofficer ChairmanP-PurchaseBuy28,000$4.58$128.24K169,856
Dec 28, 2022Williams William V.officer President, CEOP-PurchaseBuy2,530$1.94$4.91K29,802
Dec 20, 2022Bondarenko Jamiesondirector-P-PurchaseBuy22,000$5.35$117.70K141,856

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 28, 2022Bondarenko Jamiesonofficer ChairmanP-PurchaseBuy28,000$4.58$128.24K169,856
Dec 28, 2022Williams William V.officer President, CEOP-PurchaseBuy2,530$1.94$4.91K29,802
Dec 20, 2022Bondarenko Jamiesondirector-P-PurchaseBuy22,000$5.35$117.70K141,856

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 11, 2022Bondarenko Jamiesondirector-Sell---119,856
Aug 11, 2022Bondarenko Jamiesondirector-Sell150,000$4.24$636.00K-
Aug 11, 2022Bondarenko Jamiesondirector-Sell250,000$8.47$2.12M-
Aug 11, 2022Bondarenko Jamiesondirector-Sell70,000$5.31$371.70K-
Aug 01, 2022Del Priore Giuseppeofficer Chief Medical OfficerSell150,000$7.51$1.13M-
Aug 01, 2022Taub Rebeccadirector-Sell10,000$4.24$42.40K-
Aug 01, 2022Taub Rebeccadirector-Sell10,000$8.47$84.70K-
Aug 01, 2022Lopez-Lago Miguel A.officer Chief Scientific OfficerSell15,000$8.47$127.05K-
Aug 01, 2022Schmieg Martin E.director-Sell---575
Aug 01, 2022Schmieg Martin E.director-Sell25,000$4.24$106.00K-
Aug 01, 2022Schmieg Martin E.director-Sell50,000$8.47$423.50K-
Aug 01, 2022Embro-Pantalony Vaughn C.director-Sell25,000$4.24$106.00K-
Aug 01, 2022Embro-Pantalony Vaughn C.director-Sell50,000$8.47$423.50K-
Aug 01, 2022Williams Williams V.director, officer President & CEOSell---149,636

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Dec 28, 2022Bondarenko Jamiesonofficer ChairmanP-PurchaseBuy28,000$4.58$128.24K169,856
Dec 28, 2022Williams William V.officer President, CEOP-PurchaseBuy2,530$1.94$4.91K29,802
Dec 20, 2022Bondarenko Jamiesondirector-P-PurchaseBuy22,000$5.35$117.70K141,856
Aug 11, 2022Bondarenko Jamiesondirector-Sell---119,856
Aug 11, 2022Bondarenko Jamiesondirector-Sell150,000$4.24$636.00K-
Aug 11, 2022Bondarenko Jamiesondirector-Sell250,000$8.47$2.12M-
Aug 11, 2022Bondarenko Jamiesondirector-Sell70,000$5.31$371.70K-
Aug 02, 2022Lustig Marcdirector-Buy---1,640,000
Aug 02, 2022Lustig Marcdirector-Buy20,000$5.31$106.20K-
Aug 01, 2022Del Priore Giuseppeofficer Chief Medical OfficerSell150,000$7.51$1.13M-
Aug 01, 2022Taub Rebeccadirector-Sell10,000$4.24$42.40K-
Aug 01, 2022Taub Rebeccadirector-Sell10,000$8.47$84.70K-
Aug 01, 2022Lopez-Lago Miguel A.officer Chief Scientific OfficerSell15,000$8.47$127.05K-
Aug 01, 2022Schmieg Martin E.director-Sell---575
Aug 01, 2022Schmieg Martin E.director-Sell25,000$4.24$106.00K-
Aug 01, 2022Schmieg Martin E.director-Sell50,000$8.47$423.50K-
Aug 01, 2022Embro-Pantalony Vaughn C.director-Buy---9,524
Aug 01, 2022Embro-Pantalony Vaughn C.director-Sell25,000$4.24$106.00K-
Aug 01, 2022Embro-Pantalony Vaughn C.director-Sell50,000$8.47$423.50K-
Aug 01, 2022Williams Williams V.director, officer President & CEOSell---149,636

The last insider sell of BriaCell Therapeutics's stock was made by Bondarenko Jamieson on Aug 11 2022, selling - shares at - per share (valued at -). The last insider buy of BCTX was made by Bondarenko Jamieson on Dec 28 2022, buying 28,000 shares at $4.58 per share (worth $128.24K).

BriaCell Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q4 20223--
Q3 2022-14-
Q1 2022---
Q4 2021-1-
Q3 2021-1-
Q1 2021-6-

3 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by BriaCell Therapeutics's insiders, as of Q4 2022.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q4 20223--
Q3 2022---
Q1 2022---
Q4 2021---
Q3 2021---
Q1 2021---

As of Q4 2022, Insider owners conducted 3 open market buy trades and 0 open market sell trades of BriaCell Therapeutics's stocks.

BriaCell Therapeutics Peer Ownership


TickerCompany
TERNTerns Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
ELEVElevation Oncology, Inc.
XFORX4 Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
EFTReFFECTOR Therapeutics, Inc.
HOOKHOOKIPA Pharma Inc.
HEPAHepion Pharmaceuticals, Inc.

BCTX Ownership FAQ


BriaCell Therapeutics is owned by institutional shareholders (0.00%), insiders (15.56%), and public (84.44%). The largest institutional shareholder of BriaCell Therapeutics is ROSENBERG MATTHEW HAMILTON (0.00% of total shares) and the top mutual fund owner is WASATCH FUNDS TRUST (0.07% of total shares).

BriaCell Therapeutics's major institutional shareholders are ROSENBERG MATTHEW HAMILTON, and ADVISORY SERVICES NETWORK, LLC. The top five shareholders own together 0.00% of the company's share outstanding.

As of Mar 2024, there are 1 institutional shareholders of BriaCell Therapeutics.

ROSENBERG MATTHEW HAMILTON owns 12 shares of BriaCell Therapeutics, representing 0.00% of the company's total shares outstanding, valued at $34 (as of Mar 2024).

As of Mar 2024, ADVISORY SERVICES NETWORK, LLC holds 0 shares of BriaCell Therapeutics (BCTX), compromising 0% of the company, valued at $0.